Scroll for more

BenevolentAI isn’t just another ‘tech company’

It is one that’s harnessing artificial intelligence to augment and accelerate the rate at which humans can create solutions to solve some of the world’s biggest challenges.

We’re passionate about new ideas that can change the health of millions.

The diversity of our people and their ideas inspire the innovation that runs through everything we do, from amazing technology to the creation of better medicines.

our story

Since our foundation in 2013, our mission has been to bring the power of humans and machines together to make sense of, and drive rapid scientific discovery.

Based in London’s Kings Cross Knowledge Quarter, BenevolentAI was founded in 2013 by the management team of Proximagen who have a track record in building highly successful and disruptive technology companies.

We saw the opportunity to forge a powerful union between humans, technology and bioscience using AI. The purpose of this was to accelerate global scientific discovery by turning the world’s highly fragmented scientific information into new insight and usable knowledge that ultimately benefits society.

Our unique proprietary AI technology, the Judgement Augmented Cognition System (JACS), is at the core of everything we do. JACS uses cutting edge deep learning techniques to change the way knowledge is created, connected and applied and enables the mass analysis of vast amounts of scientific information. This provides experienced scientists with the augmented insight and analytical tools they need to use previously impenetrable complex and deep knowledge to dramatically speed up scientific discovery.

In September 2016, BenevolentAI created two distinct business units; ‘BenevolentBio’ (formerly Stratified Medical) which applies BenevolentAI’s technology in human health and the exploration of further bioscience applications, and, ‘BenevolentTech’ which refines and develops the company’s technology and replicates our initial success across wider applications and industries. These two companies work together symbiotically, creating a virtuous circle of AI development and drive our overall purpose – a technology company specialising in the application of AI for a broad range of benevolent uses.

BenevolentBio

BenevolentBio is responsible for applying the company’s technology in the human health and bioscience sectors.

Currently the company is focused on the disease areas of inflammation, neurodegeneration (e.g. Parkinson’s, Alzheimer’s), orphan diseases (e.g. Amyotrophic Lateral Sclerosis - ‘ALS’) and rare cancers.

However, given the scope of BenevolentAI’s artificial intelligence and machine learning capabilities the company aims to remain as flexible as possible should sufficiently interesting opportunities present themselves in the future.

Other potential applications of the company’s technology could see the team move into other areas of biomedical discovery particularly relating to women’s health, rare human diseases, veterinary medicine, nutraceuticals, cosmeceuticals and agri-tech.

BenevolentTech

BenevolentTech is responsible for refining the company’s technology and developing its use for numerous industry sectors.

At the heart of BenevolentTech is the artificial intelligence technology that the company has developed – its Judgment Augmented Cognition System (JACS).

The system uses cutting edge deep learning techniques to enable the analysis of vast quantities of scientific information to change the way knowledge is actually created.

The main advantage of the system is that the knowledge it creates is usable and can be applied in the real world setting in conjunction with the support of human experts.

our neighbourhood

BenevolentAI is headquartered in the ‘Knowledge Quarter’ tech cluster in Kings Cross, London - a neighbourhood of highly respected academic institutions and technology innovators including Google, Facebook, The Alan Turing Institute, The Francis Crick Institute, Wellcome Trust, Digital Catapult and University College London. We also have offices in Belgium and New York.

72,000 people

73 organisations

1 mile radius

KQ

join our team

Every day is an opportunity, if you are talented, ambitious and share our values, contact us.

BenevolentBio

If battling diseases is your thing, come and join the team to help deliver the next big drug discovery

View jobs

BenevolentTech

Come join the team and help us develop the next major breakthrough in applied AI technology

View jobs